Glut10 is a Novel Immune Regulator Involved in Lung Cancer Immune Cell Infiltration and Predicts Worse Survival When Transcriptionally Down-Regulated

Abstract Background: GLUT10 is encoded by SLC2A10 gene. Recent investigations have shown that GLUT10 is not only involved in glucose metabolism, but also involved in the body's immune response to cancer cells. However, the correlations between GLUT10 expression and prognosis, immune cells infiltrating of different cancers remain unclear.Methods: We Knocked down SLC2A10 and performed transcriptome sequencing to analyze the biological function of GLUT10. The SLC2A10 expression level was analyzed by the Oncomine databases and Tumor immune Estimation Resource (TIMER) site. We evaluated the prognostic potential of SLC2A10 in different cancers using the Kaplan-Meier plotter database and the PrognoScan online software. The correlations between SLC2A10 expression and immune infiltrates were analyzed by TIMER. In addition, correlations between SLC2A10 expression and gene marker sets of immune infiltrates were analyzed by TIMER and GEPIA.Results: Knocking down of SLC2A10 widely activated immune and inflammatory signaling. SLC2A10 was abnormally expressed in several tumors. The expression level of SLC2A10 was closely correlated with cancer prognosis. Low SLC2A10 expression was related to poorer prognosis and increased malignancy of lung cancer. Lung cancer patients with low expression of SLC2A10 have a much shorter median survival time than patients with high expression of SLC2A10. SLC2A10 expression is closely related to different types of immune cell infiltration, particularly with macrophages.Conclusions: By using various databases and analysis software, we found that GLUT10 is involved in tumor immunity and is expected to serve as a therapeutic target in the future. Down-regulation of SLC2A10 expression predicts poor prognosis of lung cancer. GLUT10 may be a new important immune regulating molecular thus worth further focusing.